Show simple item record

dc.contributor.authorBewick, Tom
dc.contributor.authorGreenwood, S
dc.date.accessioned2018-03-07T17:25:19Z
dc.date.available2018-03-07T17:25:19Z
dc.date.issued2018-02
dc.identifier.citationVaccine. 2018 Feb 10. pii: S0264-410X(18)30169-5. doi: 10.1016/j.vaccine.2018.02.005. [Epub ahead of print]en
dc.identifier.urihttps://orda.derbyhospitals.nhs.uk/handle/123456789/1492
dc.descriptionAuthor(s) Pre or Post Print Version Onlyen
dc.description.abstractThere is debate regarding the value of vaccinating adults with the 13-valent pneumococcal conjugate vaccine (PCV-13). This analysis was conducted to investigate the risk of PCV-13 serotype community acquired pneumonia (CAP) in hospitalised adults with co-morbid disease and risk factors for pneumococcal disease in the UK. Consecutive adults hospitalised (2008-2013) with a primary diagnosis of CAP, were recruited. Pneumococcal aetiology disease was identified by use of pneumococcal urinary antigen detection and serotype identification using a validated multiplex immunoassay or serum latex agglutination. Adults with PCV-13 serotype CAP were compared to those with non-PCV-13 serotype CAP. Of 2224 patients, PCV-13 serotype CAP was identified in 337 (15.2%) and non-PCV-13 serotype CAP in 250 (11.2%) individuals. Adults aged ≥65 years with one or more clinical risk factors had a significantly lower risk of PCV-13 serotype CAP compared to those aged 16-64 years without clinical risk factors (aOR 0.61, 95%CI 0.41-0.92, p = .018). In a stacked-risk analysis, the presence of incremental clinical risk factors was associated with lower odds of PCV-13 disease (p for trend = .029) Adults with underlying chronic respiratory disease (aOR) 0.56, 95% CI 0.36-0.85, p = .007) and chronic kidney disease (aOR 0.48, 95% CI 0.25-0.92, p = .028) had significantly lower adjusted odds of PCV-13 compared to non-PCV-13 serotype CAP. This analysis suggests that in the UK, the burden of PCV13 disease is greater in adults outside the traditional 'at-risk' groups compared to adults in 'at-risk' groups.en
dc.language.isoenen
dc.subjectPCV-13en
dc.subjectPneumoniaen
dc.subjectSerotypesen
dc.subjectStreptococcus Pneumoniaeen
dc.subjectVaccineen
dc.title13-Valent vaccine serotype pneumococcal community acquired pneumonia in adults in high clinical risk groups.en
dc.typeArticleen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record